company background image
FRE

Fresenius SE KGaA XTRA:FRE Stock Report

Last Price

€28.10

Market Cap

€15.7b

7D

-2.8%

1Y

-36.8%

Updated

25 Jun, 2022

Data

Company Financials +
FRE fundamental analysis
Snowflake Score
Valuation6/6
Future Growth3/6
Past Performance3/6
Financial Health4/6
Dividends5/6

FRE Stock Overview

Fresenius SE & Co. KGaA, a health care company, provides products and services for dialysis, hospitals, and outpatient medical care.

Fresenius SE KGaA Competitors

 

 

 

 

 

 

 

 

 

 

 

 

Price History & Performance

Summary of all time highs, changes and price drops for Fresenius SE KGaA
Historical stock prices
Current Share Price€28.10
52 Week High€47.60
52 Week Low€26.52
Beta1.21
1 Month Change-12.68%
3 Month Change-14.33%
1 Year Change-36.83%
3 Year Change-41.07%
5 Year Change-62.56%
Change since IPO2,388.94%

Recent News & Updates

Apr 28
Fresenius SE KGaA (ETR:FRE) Is Increasing Its Dividend To €0.92

Fresenius SE KGaA (ETR:FRE) Is Increasing Its Dividend To €0.92

The board of Fresenius SE & Co. KGaA ( ETR:FRE ) has announced that it will be increasing its dividend on the 13th of...

Apr 17
At €34.09, Is Fresenius SE & Co. KGaA (ETR:FRE) Worth Looking At Closely?

At €34.09, Is Fresenius SE & Co. KGaA (ETR:FRE) Worth Looking At Closely?

Let's talk about the popular Fresenius SE & Co. KGaA ( ETR:FRE ). The company's shares led the XTRA gainers with a...

Apr 02
Fresenius SE KGaA (ETR:FRE) Is Paying Out A Larger Dividend Than Last Year

Fresenius SE KGaA (ETR:FRE) Is Paying Out A Larger Dividend Than Last Year

Fresenius SE & Co. KGaA's ( ETR:FRE ) dividend will be increasing to €0.92 on 13th of June. Based on the announced...

Mar 27
Fresenius SE KGaA (ETR:FRE) Could Be Struggling To Allocate Capital

Fresenius SE KGaA (ETR:FRE) Could Be Struggling To Allocate Capital

If you're looking for a multi-bagger, there's a few things to keep an eye out for. Firstly, we'll want to see a proven...

Shareholder Returns

FREDE HealthcareDE Market
7D-2.8%-3.3%-0.1%
1Y-36.8%-29.9%-22.0%

Return vs Industry: FRE underperformed the German Healthcare industry which returned -29.9% over the past year.

Return vs Market: FRE underperformed the German Market which returned -22% over the past year.

Price Volatility

Is FRE's price volatile compared to industry and market?
FRE volatility
FRE Average Weekly Movement3.8%
Healthcare Industry Average Movement4.1%
Market Average Movement5.6%
10% most volatile stocks in DE Market10.0%
10% least volatile stocks in DE Market2.8%

Stable Share Price: FRE is less volatile than 75% of German stocks over the past 3 months, typically moving +/- 4% a week.

Volatility Over Time: FRE's weekly volatility (4%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
1912317,242Stephan Sturmhttps://www.fresenius.com

Fresenius SE & Co. KGaA, a health care company, provides products and services for dialysis, hospitals, and outpatient medical care. It operates through four segments: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed. The Fresenius Medical Care segment offers products and services for patients with chronic kidney failure.

Fresenius SE KGaA Fundamentals Summary

How do Fresenius SE KGaA's earnings and revenue compare to its market cap?
FRE fundamental statistics
Market Cap€15.69b
Earnings (TTM)€1.80b
Revenue (TTM)€38.26b

8.7x

P/E Ratio

0.4x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
FRE income statement (TTM)
Revenue€38.26b
Cost of Revenue€27.89b
Gross Profit€10.36b
Other Expenses€8.57b
Earnings€1.80b

Last Reported Earnings

Mar 31, 2022

Next Earnings Date

Aug 02, 2022

Earnings per share (EPS)3.22
Gross Margin27.08%
Net Profit Margin4.69%
Debt/Equity Ratio67.4%

How did FRE perform over the long term?

See historical performance and comparison

Dividends

3.3%

Current Dividend Yield

29%

Payout Ratio
We’ve recently updated our valuation analysis.

Valuation

Is FRE undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

6/6

Valuation Score 6/6

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • PEG Ratio

Key Valuation Metric

Which metric is best to use when looking at relative valuation for FRE?

Other financial metrics that can be useful for relative valuation.

FRE key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue1.3x
Enterprise Value/EBITDA9.4x
PEG Ratio0.8x

Price to Earnings Ratio vs Peers

How does FRE's PE Ratio compare to its peers?

FRE PE Ratio vs Peers
The above table shows the PE ratio for FRE vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPEEstimated GrowthMarket Cap
Peer Average27.8x

Price-To-Earnings vs Peers: FRE is good value based on its Price-To-Earnings Ratio (8.7x) compared to the peer average (27.8x).


Price to Earnings Ratio vs Industry

How does FRE's PE Ratio compare vs other companies in the Healthcare Industry?

Price-To-Earnings vs Industry: FRE is good value based on its Price-To-Earnings Ratio (8.7x) compared to the German Healthcare industry average (15.7x)


Price to Earnings Ratio vs Fair Ratio

What is FRE's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

FRE PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio8.7x
Fair PE Ratio24.8x

Price-To-Earnings vs Fair Ratio: FRE is good value based on its Price-To-Earnings Ratio (8.7x) compared to the estimated Fair Price-To-Earnings Ratio (24.8x).


Share Price vs Fair Value

What is the Fair Price of FRE when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: FRE (€28.1) is trading below our estimate of fair value (€199.28)

Significantly Below Fair Value: FRE is trading below fair value by more than 20%.


Price to Earnings Growth Ratio

PEG Ratio: FRE is good value based on its PEG Ratio (0.8x)


Discover undervalued companies

Future Growth

How is Fresenius SE KGaA forecast to perform in the next 1 to 3 years based on estimates from 15 analysts?

Future Growth Score

3/6

Future Growth Score 3/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


10.6%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: FRE's forecast earnings growth (10.6% per year) is above the savings rate (-0.05%).

Earnings vs Market: FRE's earnings (10.6% per year) are forecast to grow faster than the German market (8.3% per year).

High Growth Earnings: FRE's earnings are forecast to grow, but not significantly.

Revenue vs Market: FRE's revenue (4.9% per year) is forecast to grow faster than the German market (4.8% per year).

High Growth Revenue: FRE's revenue (4.9% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: FRE's Return on Equity is forecast to be low in 3 years time (10.5%).


Discover growth companies

Past Performance

How has Fresenius SE KGaA performed over the past 5 years?

Past Performance Score

3/6

Past Performance Score 3/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


-0.7%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: FRE has high quality earnings.

Growing Profit Margin: FRE's current net profit margins (4.7%) are higher than last year (4.7%).


Past Earnings Growth Analysis

Earnings Trend: FRE's earnings have declined by 0.7% per year over the past 5 years.

Accelerating Growth: FRE's earnings growth over the past year (6.7%) exceeds its 5-year average (-0.7% per year).

Earnings vs Industry: FRE earnings growth over the past year (6.7%) underperformed the Healthcare industry 44.5%.


Return on Equity

High ROE: FRE's Return on Equity (9%) is considered low.


Discover strong past performing companies

Financial Health

How is Fresenius SE KGaA's financial position?

Financial Health Score

4/6

Financial Health Score 4/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Debt Coverage

  • Interest Coverage

Financial Position Analysis

Short Term Liabilities: FRE's short term assets (€18.0B) exceed its short term liabilities (€14.1B).

Long Term Liabilities: FRE's short term assets (€18.0B) do not cover its long term liabilities (€28.4B).


Debt to Equity History and Analysis

Debt Level: FRE's net debt to equity ratio (60.7%) is considered high.

Reducing Debt: FRE's debt to equity ratio has reduced from 92.2% to 67.4% over the past 5 years.

Debt Coverage: FRE's debt is well covered by operating cash flow (21.9%).

Interest Coverage: FRE's interest payments on its debt are well covered by EBIT (7.9x coverage).


Balance Sheet


Discover healthy companies

Dividend

What is Fresenius SE KGaA current dividend yield, its reliability and sustainability?

Dividend Score

5/6

Dividend Score 5/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Future Dividend Coverage


3.27%

Current Dividend Yield

Dividend Yield vs Market

Notable Dividend: FRE's dividend (3.27%) is higher than the bottom 25% of dividend payers in the German market (1.47%).

High Dividend: FRE's dividend (3.27%) is low compared to the top 25% of dividend payers in the German market (4.53%).


Stability and Growth of Payments

Stable Dividend: FRE's dividends per share have been stable in the past 10 years.

Growing Dividend: FRE's dividend payments have increased over the past 10 years.


Earnings Payout to Shareholders

Earnings Coverage: With its reasonably low payout ratio (28.6%), FRE's dividend payments are well covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: With its low cash payout ratio (20.5%), FRE's dividend payments are well covered by cash flows.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

8.3yrs

Average management tenure


CEO

Stephan Sturm (58 yo)

17.42yrs

Tenure

€6,570,000

Compensation

Mr. Stephan Sturm serves as Chairman of the Management Board, Chief Executive Officer and President at Fresenius Management SE, the General Partner of Fresenius SE & Co KGaA since July 1, 2016 and its Memb...


CEO Compensation Analysis

Compensation vs Market: Stephan's total compensation ($USD6.93M) is about average for companies of similar size in the German market ($USD5.63M).

Compensation vs Earnings: Stephan's compensation has been consistent with company performance over the past year.


Leadership Team

Experienced Management: FRE's management team is seasoned and experienced (8.3 years average tenure).


Board Members

Experienced Board: FRE's board of directors are considered experienced (6.1 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Fresenius SE & Co. KGaA's employee growth, exchange listings and data sources


Key Information

  • Name: Fresenius SE & Co. KGaA
  • Ticker: FRE
  • Exchange: XTRA
  • Founded: 1912
  • Industry: Health Care Services
  • Sector: Healthcare
  • Implied Market Cap: €15.694b
  • Shares outstanding: 558.50m
  • Website: https://www.fresenius.com

Number of Employees


Location

  • Fresenius SE & Co. KGaA
  • Else-Kroener-Strasse 1
  • Bad Homburg vor der Höhe
  • Hessen
  • 61352
  • Germany

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/06/25 00:00
End of Day Share Price2022/06/24 00:00
Earnings2022/03/31
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.